Table 6.
The risk of developing clinically advanced disease in relation to the levels of immuno-nutritional scores.
| Parameter | Stage I, n (%) | Stage II and III, n (%) |
OR1 (95% CI) | p-Value | OR2 (95% CI) | p-Value |
|---|---|---|---|---|---|---|
| High HALP | 118 (80) | 28 (51) | 1.00 (reference group) | <0.001 * | 1.00 (reference group) | 0.001 * |
| Low HALP | 30 (20) | 27 (49) | 3.793 (1.954–7.363) | 4.161 (1.862–9.269) | ||
| High PNI | 136 (92) | 39 (71) | 1.00 (reference group) | <0.001 * | 1.00 (reference group) | |
| Low PNI | 12 (8) | 16 (29) | 4.650 (2.030–10.650) | 5.556 (1. 969–15.677) | 0.001 * |
High HALP score > 42.56; high PNI score > 52.5; OR1- crude odds ratio; OR2 is adjusted to tumor size (greater than 4 cm), smoking status and multifocality; CI-confidence interval; HALP-hemoglobin, albumin, lymphocytes and platelets score (formula: hemoglobin × albumin × lymphocytes/platelets); PNI-prognostic nutritional index (formula: albumin value + (5 × peripheral blood lymphocyte count)); * p < 0.05.